title: The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group.
abstract: OBJECTIVE
  To determine the effects of atenolol, nifedipine and their combination on exercise parameters and ambulatory ischaemic activity in patients with mild chronic stable angina.
  
  
  METHODS
  Multicentre, multinational study involving 608 patients from 69 centres in nine countries.
  
  
  METHODS
  Placebo washout followed by double-blind parallel-group study comparing atenolol 50 mg bd, nifedipine SR 20 mg bd, and their combination. Patients underwent maximal exercise testing using either a bicycle (n = 289) or treadmill (n = 319) and 48 h of ambulatory ST segment monitoring outside the hospital environment at the end of the placebo washout period and after 6 weeks of active therapy.
  
  
  RESULTS
  Both medications alone and in combination caused significant improvements in exercise parameters and significant reductions in ischaemic activity during daily activities, when compared with placebo. There were, however, no significant differences between groups, for any of the measured ischaemic parameters although combination therapy resulted in a greater fall in resting systolic and diastolic blood pressure than either treatment alone.
  
  
  CONCLUSIONS
  In the management of mild chronic stable angina there appears to be little advantage gained from using combination therapy for ischaemia reduction.
authors.affiliation: Royal Brompton Hospital, London, UK.
authors.forename: K M
authors.initials: KM
authors.lastname: Fox
authors.forename: D
authors.initials: D
authors.lastname: Mulcahy
authors.forename: I
authors.initials: I
authors.lastname: Findlay
authors.forename: I
authors.initials: I
authors.lastname: Ford
authors.forename: H J
authors.initials: HJ
authors.lastname: Dargie
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D001262:Atenolol / Q000009:adverse effects / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004562:Electrocardiography / Q000187:drug effects*; D015716:Electrocardiography, Ambulatory / Q000187:drug effects; D005060:Europe; D005080:Exercise Test / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000319:Adrenergic beta-Antagonists; D002121:Calcium Channel Blockers; D003692:Delayed-Action Preparations; D001262:Atenolol; D009543:Nifedipine